Literature DB >> 12852657

Biology and management of AIDS-associated non-Hodgkin's lymphoma.

Amy E Gates1, Lawrence D Kaplan.   

Abstract

The treatment of HIV-related lymphomas is evolving in the era of HAART. Standard-dose chemotherapy and dose-intensive therapies appear to be feasible. Whether outcomes are improved with combination chemotherapy and HAART remains unclear. Efforts aimed at developing pathogenic-based therapies will continue as the mechanisms of HIV lymphomagenesis are elucidated.

Entities:  

Mesh：

Year:  2003        PMID： 12852657     DOI： 10.1016/s0889-8588(03)00041-8

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN： 0889-8588            Impact factor:   3.722


  3 in total

1.  Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010.

Authors:  Lawrence D Kaplan; Jeannette Y Lee; Richard F Ambinder; Joseph A Sparano; Ethel Cesarman; Amy Chadburn; Alexandra M Levine; David T Scadden
Journal:  Blood       Date:  2005-05-24       Impact factor: 22.113

2.  Clinical characteristics and outcomes of newly diagnosed patients with HIV-associated aggressive B-cell NHL in China.

Authors:  Chaoyu Wang; Jun Liu; Haike Lei; Yu Li; Jian Wu; Bingling Guo; Renzhi Hu; Tingting Liu; Jing Wu; Yao Ding; Chongling Hu; Shunsi Liang; Chunyan Xiao; Xiping Liang; Dehong Huang; Tao Yang; Wenjun Zhang; Zailin Yang; Jieping Li; Yingyu Nan; Qiying Li; Ying Xiang; Zhenhua Li; Yongzhong Wu; Yao Liu
Journal:  J Cell Mol Med       Date:  2022-09-03       Impact factor: 5.295

3.  Clinical analysis of 10 AIDS patients with malignant lymphoma.

Authors:  Gui-Ju Gao; Di Yang; Ke-Ke Lin; Jiang Xiao; Xin Li; Hong-Yuan Liang; Long Liu; Ning Han; Hong-Xin Zhao
Journal:  Cancer Biol Med       Date:  2012-06       Impact factor: 4.248
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.